Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
Arthur A. Hurwitz(SUNY Upstate Medical University), James P. Allison(The University of Texas MD Anderson Cancer Center), Eugene M. Choi(University of California, Berkeley), Barbara A. Foster(Roswell Park Comprehensive Cancer Center), Tan Truong(University of California, Berkeley), Eugene D. Kwon(BC Children's Hospital), Norman M. Greenberg(Baylor College of Medicine), Maurice B. Burg(National Heart Lung and Blood Institute)
PubMed
May 1, 2000
Cited by 427
Related Papers
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Cellular Response to Hyperosmotic Stresses
|Physiological Reviews|2007|790
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739